WntResearch recently announced that the Spanish authorities have approved the revised study plan for the phase II study NeoFox with the drug candidate Foxy-5 in colon cancer. The company has introduced new endpoints on the primary tumour already at the patients' surgery, which enables significantly earlier data readout and thus cost and time savings.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.35 SEK | +28.13% |
|
+20.59% | +55.98% |
06-20 | WntResearch Presents Ad H Holes Observations from the NeoFox Study at ESMO GI | CI |
05-03 | WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+55.98% | 11.87M | |
+16.73% | 123B | |
+21.13% | 115B | |
+19.91% | 25.85B | |
-17.94% | 20.9B | |
-16.24% | 16.52B | |
-11.76% | 16.77B | |
-44.45% | 15.56B | |
+69.92% | 15.49B | |
+1.41% | 13.45B |
- Stock Market
- Equities
- WNT Stock
- News WntResearch AB
- WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study